Beam Therapeutics EBITDA margin
Qual é o EBITDA margin de Beam Therapeutics?
O EBITDA margin de Beam Therapeutics Inc. é -35.52%
Qual é a definição de EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin de empresas na Setor Health Care em NASDAQ em comparação com Beam Therapeutics
O que Beam Therapeutics faz?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Empresas com ebitda margin semelhantes a Beam Therapeutics
- Tellurian Inc tem EBITDA margin de -35.70%
- Quanterix Corp tem EBITDA margin de -35.66%
- Vicinity Motor tem EBITDA margin de -35.63%
- KNT tem EBITDA margin de -35.61%
- Medical Properties Trust Inc tem EBITDA margin de -35.61%
- Texmaco Infrastructure & tem EBITDA margin de -35.58%
- Beam Therapeutics tem EBITDA margin de -35.52%
- Oatly AB tem EBITDA margin de -35.52%
- Green International tem EBITDA margin de -35.51%
- Althea tem EBITDA margin de -35.46%
- Ambarella Inc tem EBITDA margin de -35.46%
- The Ravalgaon Sugar Farm tem EBITDA margin de -35.39%
- Oryzon Genomics S.A tem EBITDA margin de -35.35%